Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

• Published in: Cancer chemotherapy and pharmacology Vol. 67; no. 4; pp. 967 - 969
• Main Authors: Helbig, Grzegorz, Moskwa, Andrzej, Hus, Marek, Piszcz, Jarosław, Swiderska, Alina, Urbanowicz, Alina, Całbecka, Małgorzata, Seferyńska, Ilona, Raźny, Małgorzata, Rodzaj, Marek, Żuk, Ewa, Kyrcz-Krzemień, Sławomira
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.04.2011; Springer Verlag
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Benzamides; Cancer; Cancer Research; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome - drug therapy; Hypereosinophilic Syndrome - pathology; Imatinib Mesylate; Letter to the Editor; Life Sciences; Male; Medicine; Medicine & Public Health; Middle Aged; mRNA Cleavage and Polyadenylation Factors - genetics; Oncogene Proteins, Fusion - genetics; Oncology; Pharmacology/Toxicology; Piperazines - administration & dosage; Piperazines - pharmacokinetics; Piperazines - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - pharmacokinetics; Pyrimidines - therapeutic use; Receptor, Platelet-Derived Growth Factor alpha - genetics; Remission Induction - methods; Retrospective Studies; Splenomegaly - etiology; Time Factors; Young Adult; Imatinib; Molecular Remission; Imatinib Mesylate; Imatinib Dose; Durable Remission; Medicine
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-011-1582-3